Stratosvir Limited
Targeting tumours with a new method of drug delivery
Investment Overview
Minimum: £1m
Technology Stage: Seed investment
Investment Stage: Raising Investment

Share this

Targeting tumours with a new method of drug delivery

Investment Details

Therapeutic viruses have huge potential yet cannot currently be delivered intravenously, being limited to intratumoral injection. This restricts their clinical use.

Stratosvir Limited are developing a pioneering platform which is designed to relieve this crucial barrier that prevents systemic delivery. This allows their cancer-killing virus to deliver medicinal payloads within the tumour to stimulate and reprogram the immune system to attack and destroy cancer.

 

Investment Highlights
Funded by Deep Science Ventures, its partners and CRUK, Stratosvir has assembled significant expertise in virology, immunology, oncology and molecular engineering to guide its mission.
Register Your Interest
Name(Required)